MobileODT said last week that it is implementing a new artificial intelligence algorithm in its EVA system Colposcope that it claims can detect cervical cancer more effectively than existing testing.
The new technology, known as Automated Visual Evaluation, has been validated by the National Cancer Institute and the National Library of Medicine, the Israel-based company said, and is able to identify problematic lesions with greater reliability than traditional Pap Cytology testing.
MobileODT said that it is working with the NCI and other researchers to continue validating the AVE algorithm, and that it is launching a large scale pilot looking to validate the clinical application of the AVE algorithm with partners at India’s Genworks Health and Apollo Hospitals.
In the study, researchers will investigate the use of the AI algorithm in detecting cervical cancer in up to 250 women, the company said. It is hopeful that data from the trial will help improve the effectiveness of the AVE tech.
“We are excited by the new AVE algorithm and the promise it holds in fighting cervical cancer. Our team is proud to make available an AVE enabled colposcope to reach more women and save more lives,” CEO Ariel Beery said in a press release.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.